Patents by Inventor John Nemunaitis

John Nemunaitis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220151976
    Abstract: Described herein are compositions, formulations, and methods useful for sensitizing cancer cells to chemotherapeutic agents, for inhibiting expression or translation of oncogenic proteins, for inhibiting eIF4A, for inhibiting c-MYC, for reducing sternness of breast cancer cells, for treating breast cancer, for overcoming drug resistance of drug-resistant cancer cells, and for reducing tumor cell viability, involving one or more inhibitors of eIF4A, LASP1, CXCR4, CXCL8, CXCL12, ROCK1, BIRC5, MDM2, CCND1, and c-MYC.
    Type: Application
    Filed: February 17, 2020
    Publication date: May 19, 2022
    Applicant: The University of Toledo
    Inventors: Dayanidhi Raman, Cory M. Howard, John Nemunaitis, Francis Charles Brunicardi, Shi-He Liu, Amit K. Tiwari
  • Publication number: 20210220488
    Abstract: Compositions and methods for prevention of ovarian cancer recurrence and for the treatment of BRCA1/2-wild type ovarian cancer are disclosed herein. In some embodiments, the composition comprises an autologous tumor cell vaccine comprising cells genetically modified for furin knockdown and GM-CSF expression. In some embodiments, the method comprises administration of an autologous tumor cell vaccine prior to administration of a combination of the autologous tumor cell vaccine and atezolizumab. Also disclosed herein are methods for treating a cancer in an individual comprising a wild-type BRCA1 gene, a wild-type BRCA2 gene, or a combination thereof, and is identified as homologous recombination deficiency (HRD)-negative.
    Type: Application
    Filed: January 25, 2021
    Publication date: July 22, 2021
    Applicant: GRADALIS, INC.
    Inventors: JOHN NEMUNAITIS, ERNEST BOGNAR
  • Patent number: 9683237
    Abstract: The present invention includes compositions and methods for making and using a RNAi capable of reducing expression of two or more genes, comprising: a first RNAi molecule that reduces the expression of a first target gene; a second RNAi molecule that reduces the expression of the first or a second target gene; and optionally a third RNAi molecule that reduces the expression of the first, the second, or a third target gene, wherein the RNAi molecules reduce the expression level of, e.g., mutated KRAS, SRC-3, EGFR, PIK3, NCOA3, or ERalpha1, and can be, e.g., miRNAs, shRNAs, or bifunctional shRNAs.
    Type: Grant
    Filed: April 24, 2015
    Date of Patent: June 20, 2017
    Assignees: STRIKE BIO, INC., BAYLOR COLLEGE OF MEDICINE
    Inventors: Donald Rao, John Nemunaitis, Bert W. O'Malley, David Lonard
  • Publication number: 20150307885
    Abstract: The present invention includes compositions and methods for making and using a RNAi capable of reducing expression of two or more genes, comprising: a first RNAi molecule that reduces the expression of a first target gene; a second RNAi molecule that reduces the expression of the first or a second target gene; and optionally a third RNAi molecule that reduces the expression of the first, the second, or a third target gene, wherein the RNAi molecules reduce the expression level of, e.g., mutated KRAS, SRC-3, EGFR, PIK3, NCOA3, or ERalpha1, and can be, e.g., miRNAs, shRNAs, or bifunctional shRNAs.
    Type: Application
    Filed: April 24, 2015
    Publication date: October 29, 2015
    Inventors: Donald Rao, John Nemunaitis, Bert W. O'Malley, David Lonard
  • Patent number: 8916530
    Abstract: In certain embodiments, the invention provides methods for treating cancer, comprising: (a) obtaining a specimen of cancer tissue and normal tissue from a patient; (b) extracting total protein and RNA from the cancer tissue and normal tissue; (c) obtaining a protein expression profile of the cancer tissue and normal tissue; (d) identifying over-expressed proteins in the cancer tissue; (e) comparing the protein expression profile to a gene expression profile; (f) identifying at least one prioritized protein target by assessing connectivity of each said over-expressed protein to other cancer-related or stimulatory proteins; (g) designing a first RNA interference expression cassette to modulate the expression of at least one gene encoding the prioritized target protein; (h): designing a first RNA interference expression cassette to modulate the expression of at least one gene encoding a protein of higher priority in the signaling pathway in which the first protein is a component; (i) incorporating the first cass
    Type: Grant
    Filed: October 30, 2009
    Date of Patent: December 23, 2014
    Assignee: Gradalis, Inc.
    Inventors: David Shanahan, John Nemunaitis, Neil Senzer, Phillip Maples, Donald Rao
  • Patent number: 8603991
    Abstract: Methods for treating cancer that include (a) obtaining a specimen of cancer issue from a patient; (b) obtaining a specimen of normal tissue in the proximity of the cancer tissue; (c) extracting total protein from the cancer tissue and normal tissue; (d) obtaining a protein expression profile of the cancer tissue and normal tissue; (e) identifying a group of proteins that are expressed in the cancer tissue at significantly different levels than in the normal tissue; (f) identifying one or more prioritized proteins from the group of proteins, which will serve as the target for an RNA interference molecule (RNAi), which, when provided to a patient, will reduce the expression level of the one or more prioritized proteins using both cleavage-dependent and cleavage-independent pathways of the RNA-induced silencing complex (RISC).
    Type: Grant
    Filed: November 17, 2006
    Date of Patent: December 10, 2013
    Assignee: Gradalis, Inc.
    Inventors: David Shanahan, John Nemunaitis, Neil Senzer, Phillip Maples, Donald Rao
  • Publication number: 20100166845
    Abstract: In certain embodiments, the invention provides methods for treating cancer, comprising: (a) obtaining a specimen of cancer tissue and normal tissue from a patient; (b) extracting total protein and RNA from the cancer tissue and normal tissue; (c) obtaining a protein expression profile of the cancer tissue and normal tissue; (d) identifying over-expressed proteins in the cancer tissue; (e) comparing the protein expression profile to a gene expression profile; (f) identifying at least one prioritized protein target by assessing connectivity of each said over-expressed protein to other cancer-related or stimulatory proteins; (g) designing a first RNA interference expression cassette to modulate the expression of at least one gene encoding the prioritized target protein; (h): designing a first RNA interference expression cassette to modulate the expression of at least one gene encoding a protein of higher priority in the signaling pathway in which the first protein is a component; (i) incorporating the first cass
    Type: Application
    Filed: October 30, 2009
    Publication date: July 1, 2010
    Applicant: GRADALIS, INC.
    Inventors: David Shanahan, John Nemunaitis, Neil Senzer, Phillip Maples, Donald Rao
  • Publication number: 20070248659
    Abstract: In certain preferred embodiments, the invention provides methods for treating cancer, which comprise (a) obtaining a specimen of cancer tissue from a patient; (b) obtaining a specimen of normal tissue in the proximity of the cancer tissue from such patient; (c) extracting total protein and RNA from the cancer tissue and normal tissue; (d) obtaining a protein expression profile of the cancer tissue and normal tissue using 2D DIGE and mass spectrometry; (e) identifying proteins that are expressed in such cancer tissue at significantly different levels than in the normal tissue; (f) obtaining a gene expression profile of the cancer tissue and normal tissue using microarray technology and comparing the results thereof to the protein expression profile; (g) prioritizing over-expressed proteins by assessing the connectivity thereof to other cancer-related or stimulatory proteins; (h) designing an appropriate RNA interference expression cassette to, directly or indirectly, modulate the expression of genes encoding s
    Type: Application
    Filed: November 17, 2006
    Publication date: October 25, 2007
    Inventors: David Shanahan, John Nemunaitis, Neil Senzer, Phillip Maples, Donald Rao